221 related articles for article (PubMed ID: 11160856)
1. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.
Schmidt K; Schrammel A; Koesling D; Mayer B
Mol Pharmacol; 2001 Feb; 59(2):220-4. PubMed ID: 11160856
[TBL] [Abstract][Full Text] [Related]
2. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
[TBL] [Abstract][Full Text] [Related]
3. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide.
Hoenicka M; Becker EM; Apeler H; Sirichoke T; Schröder H; Gerzer R; Stasch JP
J Mol Med (Berl); 1999 Jan; 77(1):14-23. PubMed ID: 9930922
[TBL] [Abstract][Full Text] [Related]
4. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Turgut NH; Temiz TK; Turgut B; Karadas B; Parlak M; Bagcivan I
Can J Physiol Pharmacol; 2013 Oct; 91(10):797-803. PubMed ID: 24144050
[TBL] [Abstract][Full Text] [Related]
6. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
[TBL] [Abstract][Full Text] [Related]
7. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
8. [YC-1-like potentiation of nitric oxide-dependent activation of soluble guanylyl cyclase by adrenochrome].
Severina IS; Piatakova NV; Shchegolev AIu; Sidorova TA
Biomed Khim; 2008; 54(6):679-86. PubMed ID: 19205427
[TBL] [Abstract][Full Text] [Related]
9. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Nakane M; Hsieh G; Miller LN; Chang R; Terranova MA; Moreland RB; Kolasa T; Brioni JD
Int J Impot Res; 2002 Apr; 14(2):121-7. PubMed ID: 11979328
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
11. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of YC-1-induced activation of soluble guanylyl cyclase.
Friebe A; Koesling D
Mol Pharmacol; 1998 Jan; 53(1):123-7. PubMed ID: 9443939
[TBL] [Abstract][Full Text] [Related]
14. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
16. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.
Martin E; Lee YC; Murad F
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12938-42. PubMed ID: 11687640
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.
Garthwaite G; Goodwin DA; Neale S; Riddall D; Garthwaite J
Mol Pharmacol; 2002 Jan; 61(1):97-104. PubMed ID: 11752210
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
19. Activation of soluble guanylyl cyclase inhibits estradiol production and cyclic AMP accumulation from cultured rat granulosa cells.
Tafoya MA; Chen JY; Stewart RL; Lapolt PS
Fertil Steril; 2004 Oct; 82 Suppl 3():1154-9. PubMed ID: 15474089
[TBL] [Abstract][Full Text] [Related]
20. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
